Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 4
1998 6
1999 13
2000 9
2001 12
2002 18
2003 23
2004 19
2005 19
2006 20
2007 10
2008 14
2009 16
2010 6
2011 8
2012 12
2013 11
2014 11
2015 7
2016 13
2017 4
2019 3
2020 4
2021 2
2022 2
2023 3
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

246 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial.
Mahatme MS, Dakhale GN, Tadke K, Hiware SK, Dudhgaonkar SD, Wankhede S. Mahatme MS, et al. Indian J Pharmacol. 2016 Nov-Dec;48(6):649-653. doi: 10.4103/0253-7613.194854. Indian J Pharmacol. 2016. PMID: 28066101 Free PMC article. Clinical Trial.

The mean change of TNSS, i.e., 9.46 was significant (P < 0.05) in montelukast-fexofenadine group. The cost-effectiveness ratio was less in montelukast-levocetirizine group than in montelukast-fexofenadine group. CONCLUSION: The decrease in TNSS was more in montel

…

The mean change of TNSS, i.e., 9.46 was significant (P < 0.05) in montelukast-fexofenadine group. The cost-effectiveness ratio was

…
Bioequivalence of 2 Pediatric Formulations of Fexofenadine Hydrochloride Oral Suspension.
Rauch C, Lucio L, De Fer BB, Lheritier-Barrand M. Rauch C, et al. Clin Pharmacol Drug Dev. 2023 Dec;12(12):1194-1203. doi: 10.1002/cpdd.1311. Epub 2023 Sep 1. Clin Pharmacol Drug Dev. 2023. PMID: 37655364 Clinical Trial.
Plasma concentrations of fexofenadine were similar following the administration of a single dose of each formulation. ...There were no serious adverse events (AEs) or study discontinuations due to treatment-emergent AEs with either fexofenadine HCl formulation. The …
Plasma concentrations of fexofenadine were similar following the administration of a single dose of each formulation. ...There were n …
Comparative Efficacy of Fexofenadine Versus Levocetrizine Versus Desloratadine via 1% Histamine Wheal Suppression Test.
Kc S , Aryal A , Adhikary M , Karn D . Kc S , et al. Kathmandu Univ Med J (KUMJ). 2020 Jan.-Mar;18(69):19-22. Kathmandu Univ Med J (KUMJ). 2020. PMID: 33582682 Clinical Trial.
Subjects were randomized into 3 groups using an envelope method. First group received fexofenadine (N=36), second group received levocetrizine (N =37), and third group received desloratadine (N=29). ...However by 2 and 4 hours all three antihistamines; fexofenadine, …
Subjects were randomized into 3 groups using an envelope method. First group received fexofenadine (N=36), second group received levo …
Repurposing fexofenadine as a promising candidate for diabetic kidney disease: randomized clinical trial.
El-Fatatry BM, El-Haggar SM, Ibrahim OM, Shalaby KH. El-Fatatry BM, et al. Int Urol Nephrol. 2024 Apr;56(4):1395-1402. doi: 10.1007/s11255-023-03804-w. Epub 2023 Sep 23. Int Urol Nephrol. 2024. PMID: 37741921 Free PMC article. Clinical Trial.
Patients were randomized into two groups, the fexofenadine group (n = 30): received ramipril plus fexofenadine, and the control group (n = 31): received ramipril only for six months. ...This reduction was not reported in the fexofenadine group. Fexofenadin …
Patients were randomized into two groups, the fexofenadine group (n = 30): received ramipril plus fexofenadine, and the contro …
Combination therapy of fexofenadine and montelukast is effective in prurigo nodularis and pemphigoid nodularis.
Shintani T, Ohata C, Koga H, Ohyama B, Hamada T, Nakama T, Furumura M, Tsuruta D, Ishii N, Hashimoto T. Shintani T, et al. Dermatol Ther. 2014 May-Jun;27(3):135-9. doi: 10.1111/dth.12094. Epub 2013 Sep 17. Dermatol Ther. 2014. PMID: 24102897 Clinical Trial.
All patients received 10 mg montelukast once a day and 240 mg fexofenadine twice a day for 4 weeks in addition to other medications they had been taking. ...This study revealed that combination therapy of fexofenadine and montelukast was effective for some patients …
All patients received 10 mg montelukast once a day and 240 mg fexofenadine twice a day for 4 weeks in addition to other medications t …
Exposure of Fexofenadine, but Not Pseudoephedrine, Is Markedly Decreased by Green Tea Extract in Healthy Volunteers.
Misaka S, Ono Y, Taudte RV, Hoier E, Ogata H, Ono T, König J, Watanabe H, Fromm MF, Shimomura K. Misaka S, et al. Clin Pharmacol Ther. 2022 Sep;112(3):627-634. doi: 10.1002/cpt.2682. Epub 2022 Jun 29. Clin Pharmacol Ther. 2022. PMID: 35678032 Free PMC article. Clinical Trial.
There were no differences in time to maximum plasma concentration and the elimination half-life of fexofenadine between phases. Fexofenadine was confirmed to be a substrate of OATP1A2, and EGCG (100 and 1,000 muM) and GTE (0.1 and 1 mg/mL) inhibited OATP1A2-mediated …
There were no differences in time to maximum plasma concentration and the elimination half-life of fexofenadine between phases. Fe …
Comparative effects of fexofenadine and montelukast on allergen-induced wheal and flare.
White M, Rothrock S, Meeves S, Liao Y, Georges G. White M, et al. Allergy Asthma Proc. 2005 May-Jun;26(3):221-8. Allergy Asthma Proc. 2005. PMID: 16119039 Clinical Trial.
Fexofenadine had greater suppression than montelukast for both wheal and flare from 40 minutes through 24 hours (p < .05). Maximum suppression of flare and wheal reached 79.0 and 72.3% for fexofenadine, and 7.3 and 9.6% for montelukast. Fexofenadine suppre …
Fexofenadine had greater suppression than montelukast for both wheal and flare from 40 minutes through 24 hours (p < .05). Maximum …
Severity of coeliac disease and clinical management study when using a non-metabolised medication: a phase I pharmacokinetic study.
Chretien ML, Bailey DG, Asher L, Parfitt J, Driman D, Gregor J, Dresser GK. Chretien ML, et al. BMJ Open. 2023 Feb 24;13(2):e057151. doi: 10.1136/bmjopen-2021-057151. BMJ Open. 2023. PMID: 36828648 Free PMC article. Clinical Trial.
MAIN OUTCOME MEASURES: Patients with coeliac disease-duodenal histology and oral fexofenadine pharmacokinetics within a 3-week period. Healthy individuals-oral fexofenadine pharmacokinetics with water and grapefruit juice. ...Coeliac groups had a positive linear tre …
MAIN OUTCOME MEASURES: Patients with coeliac disease-duodenal histology and oral fexofenadine pharmacokinetics within a 3-week period …
A non-comparative trial of the efficacy and safety of fexofenadine for treatment of perennial allergic rhinitis.
Bunnag C, Jareoncharsri P, Tunsuriyawong P, Pumhirun P, Limprasertsiri S, Chochaipanichnon L, Supiyaphun P, Kongpatanakul S. Bunnag C, et al. Asian Pac J Allergy Immunol. 2000 Sep;18(3):127-33. Asian Pac J Allergy Immunol. 2000. PMID: 11270466 Free article. Clinical Trial.
Mean age was 33 years, average duration of symptoms was 6 years. All patients received fexofenadine hydrochloride 120 mg once daily (OD) in the morning for 2 weeks. Patients recorded their allergy symptoms daily using a 5 point rating scales in the diary card. ...Drowsines …
Mean age was 33 years, average duration of symptoms was 6 years. All patients received fexofenadine hydrochloride 120 mg once daily ( …
Bioavailability assessment of fexofenadine and montelukast in a fixed-dose combination tablet versus the components administered simultaneously.
Everardo PG, Magdalena GS, Maria Elena GP, Vanessa CM, Gabriela SC. Everardo PG, et al. Allergol Immunopathol (Madr). 2021 Jul 1;49(4):15-25. doi: 10.15586/aei.v49i4.89. eCollection 2021. Allergol Immunopathol (Madr). 2021. PMID: 34224214 Clinical Trial.
This study aimed to evaluate the bioequivalence of fexofenadine and montelukast in a fixed-dose combination tablet versus the components administered simultaneously. MATERIALS AND METHODS: An open, randomized, 22 crossover study was performed in 78 healthy volunteers. F …
This study aimed to evaluate the bioequivalence of fexofenadine and montelukast in a fixed-dose combination tablet versus the compone …
246 results